Brief: OPKO Health Q2 Net Income USD -148.4 Million

OPKO Health

31/07/2025 21:05

Overview

OPKO Q2 revenue falls to $156.8 mln from $182.2 mln in 2024

The biopharmaceutical and diagnostics company's net loss widens to $148.4 mln, impacted by $91.7 mln non-recurring expense

Board authorizes additional $100 mln for stock repurchase program, bringing total capacity to $200 mln

Result Drivers

PHARMACEUTICAL REVENUE - Stable at $40.7 mln due to higher sales volumes in international operations, offset by reduced sales in Chile

DIAGNOSTICS REVENUE - Declined to $101.1 mln, primarily due to lower clinical test volume following asset sales

R&D EXPENSES - Increased due to growth in BARDA collaborations and preparation for investigational new drug applications

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue from Services
$101.10 mln
Q2 Net Income
-$148.40 mln
Q2 Basic EPS
-$0.19
Q2 Operating Income
-$60 mln
Q2 Pretax Profit
-$162.50 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 55.3% above its July 30 closing price of $1.34

Press Release: ID:nGNX7lWqfG

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)